Age and Ageing Advance Access published online on November 22, 2005
Age and Ageing, doi:10.1093/ageing/afi212
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Geriatric Medicine, Wythenshawe Hospital, Manchester, UK
* To whom correspondence should be addressed. Clostridium difficile (CD)-associated diarrhoea and colitis may relapse in up to 20% of treated patients. We present a patient who failed to respond over a 6-month period to treatment either singly or in combination with metronidazole, vancomycin, rifampicin, cholestyramine and probiotics. Her diarrhoea rapidly resolved after a 3-day course of intravenous immunoglobulin. This treatment may compensate for a failed immune response to CD toxin and should be considered for relapsing CD-associated diarrhoea where there is no response to conventional treatment strategies.
Received February 16, 2005
Accepted August 24, 2005
Case Report
Intravenous immunoglobulin for resistant Clostridium difficile infection
C. Murphy 1 *,
M. Vernon 1,
and
M. Cullen 1
C. Murphy, E-mail: drclmurphy{at}aol.com
![]()
Abstract ![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
T. Z Jodlowski, R. Oehler, L. W Kam, and I. Melnychuk Emerging Therapies in the Treatment of Clostridium difficile-Associated Disease Ann. Pharmacother., December 1, 2006; 40(12): 2164 - 2169. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Surowiec, A. G Kuyumjian, M. A Wynd, and C. E Cicogna Past, Present, and Future Therapies for Clostridium difficile-Associated Disease Ann. Pharmacother., December 1, 2006; 40(12): 2155 - 2163. [Abstract] [Full Text] [PDF] |
||||
